Efficacy and Safety of QAX576 in Patients With Eosinophilic Esophagitis

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2009
This study is designed to investigate the effects of a 12 week course of intravenous QAX576 6mg/kg every 4 weeks in reducing the number of eosinophils in the esophagus of EoE patients by 75% or greater when compared with baseline.
Epistemonikos ID: 24ec415c0a69230c626d57f8eed5581721cf4790
First added on: May 05, 2024